碳青霉烯类治疗铜绿假单胞菌肺炎的临床效果分析(1)
摘 要：目的 探究碳青霉烯类治疗铜绿假单胞菌肺炎的效果。方法 选取2017年1月～2018年1月收治的86例PA肺炎患者临床资料进行分析，随机分为对照组和研究组，每组43例。对照组行头孢哌酮钠舒巴坦钠治疗，研究组行碳青霉烯类双联法治疗，比较两组肺功能(FEV1/FVC、FEV1)、实验室指标(CRP、PCT、WBC)及生活质量(SGRQ评分)。结果 两组患者治疗后FEV1/FVC、FEV1水平均优于治疗前，且研究组改善幅度大于对照组，统计学意义显著(P<0.01)。研究组治疗后实验室各指标水平均优于治疗前，且优于对照组，统计学意义显著(P<0.01)。治疗后，研究组SGRQ评分为(30.87±3.55)分，低于对照组的(40.54±4.36)分，统计学意义显著(P<0.01)。结论 碳青霉烯类治疗铜绿假单胞菌肺炎，可有效改善患者肺功能，减轻炎症反应，提高生活质量。
关键词：碳青霉烯类；铜绿假单胞菌；肺炎
中图分类号：R563.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.039
, 百拇医药
文章编号：1006-1959(2018)13-0134-03
Abstract：Objective To explore the effect of carbapenem in the treatment of Pseudomonas aeruginosa pneumonia.Methods 86 patients with Pseudomonas aeruginosa pneumonia admitted from January 2017 to January 2018 were randomly divided into control group(n=43)and study group(n=43).The control group was treated with cefoperazone sodium sulbactam sodium，the study group was treated with carbapenem double therapy，and the pulmonary function (FEV1/FVCU，FEV1)，laboratory index(CRP，PCT，WBC)and quality of life(SGRQ score)were compared between the two groups.Results The level of FEV1/FVC，FEV1 in the two groups was better than that before treatment，and the improvement in the study group was greater than that in the control group，there was significant statistical significance(P<0.01).The level of the indicators in the laboratory after treatment was better than that before treatment，and it was better than the control group，and the statistical significance was significant(P<0.01).After treatment，the SGRQ score of the study group was(30.8±3.55)，which was lower than that of the control group(40.54±4.36)，and the statistical significance was significant(P<0.01).Conclusion Carbapenem can effectively improve pulmonary function，alleviate inflammatory reaction and improve quality of life in patients with Pseudomonas aeruginosa pneumonia.
, 百拇医药
Key words：Carbapenem；Pseudomonas aeruginosa；Pneumonia
銅绿假单胞菌(pseudomonas aeruginosa，PA)属于致病力低而抗药性较强一种杆菌，是伤口感染常见一种细菌，患者感染后渗出液、脓汁等将呈现绿色，临床可转变成化脓性病变，广泛分布于肠道、皮肤及呼吸道[1]。由于PA极易侵袭人体呼吸道，特别是对于严重基础病或免疫功能较低者，造成PA肺炎，导致临床治疗难度增大。近些年，PA肺炎发病率呈不断升高趋势，临床予以早期诊断并予以有效合理抗生素治疗具有重要价值。碳青霉烯类抗生素具抗菌广谱性，可达到良好抗菌效果，且毒性较低，属于严重细菌感染患者常用抗菌药物。本研究为明确PA肺炎患者经碳青霉烯类治疗的效果，我院针对性选取86例患者资料予以分析，并报告如下。
1资料与方法
1.1一般资料 选取2017年1月～2018年1月当阳市人民医院收治的86例PA肺炎患者临床资料，本研究经医院伦理会批准。按照随机数字表法将患者分为对照组和研究组，每组43例。对照组男23例，女20例，年龄21～67岁，平均年龄(56.13±4.28)岁；病程5～40 d，平均病程(25.17±3.46)d。研究组男24例，女19例，年龄22～68岁，平均年龄(56.26±4.31)岁；病程6～41 d，平均病程(25.22±3.54)d。两组患者性别、年龄、病程等基线资料对比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李绪定)
关键词：碳青霉烯类；铜绿假单胞菌；肺炎
中图分类号：R563.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.039
, 百拇医药
文章编号：1006-1959(2018)13-0134-03
Abstract：Objective To explore the effect of carbapenem in the treatment of Pseudomonas aeruginosa pneumonia.Methods 86 patients with Pseudomonas aeruginosa pneumonia admitted from January 2017 to January 2018 were randomly divided into control group(n=43)and study group(n=43).The control group was treated with cefoperazone sodium sulbactam sodium，the study group was treated with carbapenem double therapy，and the pulmonary function (FEV1/FVCU，FEV1)，laboratory index(CRP，PCT，WBC)and quality of life(SGRQ score)were compared between the two groups.Results The level of FEV1/FVC，FEV1 in the two groups was better than that before treatment，and the improvement in the study group was greater than that in the control group，there was significant statistical significance(P<0.01).The level of the indicators in the laboratory after treatment was better than that before treatment，and it was better than the control group，and the statistical significance was significant(P<0.01).After treatment，the SGRQ score of the study group was(30.8±3.55)，which was lower than that of the control group(40.54±4.36)，and the statistical significance was significant(P<0.01).Conclusion Carbapenem can effectively improve pulmonary function，alleviate inflammatory reaction and improve quality of life in patients with Pseudomonas aeruginosa pneumonia.
, 百拇医药
Key words：Carbapenem；Pseudomonas aeruginosa；Pneumonia
銅绿假单胞菌(pseudomonas aeruginosa，PA)属于致病力低而抗药性较强一种杆菌，是伤口感染常见一种细菌，患者感染后渗出液、脓汁等将呈现绿色，临床可转变成化脓性病变，广泛分布于肠道、皮肤及呼吸道[1]。由于PA极易侵袭人体呼吸道，特别是对于严重基础病或免疫功能较低者，造成PA肺炎，导致临床治疗难度增大。近些年，PA肺炎发病率呈不断升高趋势，临床予以早期诊断并予以有效合理抗生素治疗具有重要价值。碳青霉烯类抗生素具抗菌广谱性，可达到良好抗菌效果，且毒性较低，属于严重细菌感染患者常用抗菌药物。本研究为明确PA肺炎患者经碳青霉烯类治疗的效果，我院针对性选取86例患者资料予以分析，并报告如下。
1资料与方法
1.1一般资料 选取2017年1月～2018年1月当阳市人民医院收治的86例PA肺炎患者临床资料，本研究经医院伦理会批准。按照随机数字表法将患者分为对照组和研究组，每组43例。对照组男23例，女20例，年龄21～67岁，平均年龄(56.13±4.28)岁；病程5～40 d，平均病程(25.17±3.46)d。研究组男24例，女19例，年龄22～68岁，平均年龄(56.26±4.31)岁；病程6～41 d，平均病程(25.22±3.54)d。两组患者性别、年龄、病程等基线资料对比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李绪定)